US35104E1001
© Globe Newswire
12.12.2025
FDMT
LISTED
NASDAQ
4DMT Announces New Employment Inducement Grants
News Preview
EMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on December 9, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
FDMT
LISTED
NASDAQ
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will pr...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2025
FDMT
LISTED
NASDAQ
4DMT to Participate in 8th Annual Evercore Healthcare Conference
News Preview
EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will par...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
17.11.2025
FDMT
LISTED
NASDAQ
4DMT Appoints Kristian Humer as Chief Financial Officer
News Preview
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Krist...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
14.11.2025
FDMT
LISTED
NASDAQ
4DMT Announces New Employment Inducement Grants
News Preview
EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on November 11, 202...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
FDMT
LISTED
NASDAQ
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
News Preview
EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q3 2025 financial results...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
FDMT
LISTED
NASDAQ
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
News Preview
EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the pricing of an underw...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
FDMT
LISTED
NASDAQ
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
News Preview
EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced positive interim 1.5- to...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
FDMT
LISTED
NASDAQ
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
News Preview
EMERYVILLE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced a strategic partnership...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
FDMT
LISTED
NASDAQ
4DMT Announces New Employment Inducement Grants
News Preview
EMERYVILLE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on October 14, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.10.2025
FDMT
LISTED
NASDAQ
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
News Preview
EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will par...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.09.2025
FDMT
LISTED
NASDAQ
4DMT Announces New Employment Inducement Grants
News Preview
EMERYVILLE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 9, 20...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
25.08.2025
FDMT
LISTED
NASDAQ
4DMT to Participate in Upcoming Investor Conferences
News Preview
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will par...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.08.2025
FDMT
LISTED
NASDAQ
4DMT Announces New Employment Inducement Grants
News Preview
EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 12, 2025,...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.08.2025
FDMT
LISTED
NASDAQ
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
News Preview
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q2 2025 financial result...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.07.2025
FDMT
LISTED
NASDAQ
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
News Preview
EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced podium presentations at...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.07.2025
FDMT
LISTED
NASDAQ
4DMT Announces New Employment Inducement Grants
News Preview
EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 8, 2025, th...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2025
FDMT
LISTED
NASDAQ
4DMT Announces New Employment Inducement Grants
News Preview
EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 13, 2025, the...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
FDMT
LISTED
NASDAQ
4DMT to Participate in Upcoming Investor Conferences
News Preview
EMERYVILLE, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will part...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2025
FDMT
LISTED
NASDAQ
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
News Preview
EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the U.S. Food and Dr...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.04.2025
FDMT
LISTED
NASDAQ
4DMT Announces New Employment Inducement Grants
News Preview
EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 8, 2025,...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.02.2025
FDMT
LISTED
NASDAQ
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
News Preview
EMERYVILLE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported full year 2024 financial...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.02.2025
FDMT
LISTED
NASDAQ
4DMT to Participate in Upcoming Investor Conferences
News Preview
EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in Ma...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.02.2025
FDMT
LISTED
NASDAQ
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
News Preview
EMERYVILLE, Calif., Feb. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive initial interim 52-week data from the Phase 2b Population Extension cohort of th...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
FDMT
LISTED
NASDAQ
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
News Preview
EMERYVILLE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today reported third quarter 2024 financial results, provided operational highlights an...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2024
FDMT
LISTED
NASDAQ
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
News Preview
Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2024
FDMT
LISTED
NASDAQ
Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm
News Preview
Kaskela Law LLC announces that it is investigating 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (“4D Molecular”) on behalf of the company’s stockholders.
Since March 2024, shares of 4D Molecular’s stock have declined from a trading price of over $34.00 per share to a current price of under $17.00 per share, a decline of 50% in value.
The inves...
Themefolio
Profiler
Peergroup
© BusinessWire
12.09.2024
FDMT
LISTED
NASDAQ
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. (“4D Molecular Therapeutics” or “the Company”) (NASDAQ: FDMT) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.08.2024
FDMT
LISTED
NASDAQ
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
News Preview
EMERYVILLE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today strengthened the Company’s senior management team with the appointments of Dhaval...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2024
FDMT
LISTED
NASDAQ
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
News Preview
EMERYVILLE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive initial interim 24-week landmark data from the Population Exte...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.06.2024
FDMT
LISTED
NASDAQ
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
News Preview
EMERYVILLE, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today presented supplemental aflibercept injection-free subgroup analyses of the previo...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2024
FDMT
LISTED
NASDAQ
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
News Preview
EMERYVILLE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that interim data from the Phase 1/2 AEROW clinical trial evaluating aer...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
